Fecal calprotectin (FC) levels correlate with the disease activity of inflammatory bowel
diseases (IBD); however, the utility of FC in predicting IBD relapse remains to be …

Background The efficacy and safety of vedolizumab in bio-naïve patients with ulcerative
colitis (UC) and Crohn's disease (CD) remain unknown. Aims To perform a meta-analysis …

Abstract Background and Aims Many observational studies on the use of vedolizumab [VDZ]
in patients with Crohn's disease [CD] and ulcerative colitis [UC] have been published in the …

Background Biologically naïve patients with inflammatory bowel disease treated with
vedolizumab (VDZ) are largely underrepresented in real-world cohorts. A multi-centre …

Introduction The therapeutic armamentarium for managing Crohn's disease (CD) has
expanded significantly in recent decades. Several biologics with three different mechanisms …

OBJECTIVE: Ustekinumab (UST) is an anti-IL12/23 antibody for the treatment of Crohn's
Disease (CD). The aim of this study was to compare the efficacy and safety of UST in a large …

Inflammatory bowel disease (IBD) is a chronic inflammatory condition affecting the
gastrointestinal tract with increasing rates of incidence and prevalence across the world …

Inflammatory bowel disease (IBD) displays an increased venous and arterial thrombotic risk
despite the common occurrence of intestinal bleeding. While some of the mechanisms …

Background Vedolizumab (VDZ) can be used to treat refractory ulcerative colitis (UC) and
Crohn's disease (CD). We assessed whether there are differences in treating UC vs CD with …

Background Optimizing second-line biologic therapies for adult ulcerative colitis (UC) post
first-line failure is essential. Objective Compare second-line biologic therapy efficacy in adult …